Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 3/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ESPL1 | Q14674 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30202647 | 1.00 | VCAM1 (0.52) | VCAM1XDHALDH1A1CYP3A4LMNA | |
| SCHEMBL505035 | 0.82 | VCAM1 (0.55) | VCAM1XDHALDH1A1LMNACYP19A1 | |
| SCHEMBL7086145 | 0.81 | ALDH1A1 (0.55) | VCAM1ALDH1A1CYP3A4LMNACYP19A1 | |
| SCHEMBL19072193 | 0.81 | VCAM1 (0.53) | VCAM1XDHALDH1A1CYP3A4LMNA | |
| SCHEMBL623229 | 0.79 | XDH (0.66) | VCAM1XDHALDH1A1CYP3A4LMNA | |
| SCHEMBL11920911 | 0.79 | VCAM1 (0.52) | VCAM1XDHALDH1A1CYP3A4LMNA | |
| SCHEMBL16236822 | 0.79 | VCAM1 (0.60) | VCAM1XDHALDH1A1LMNACYP19A1 | |
| SCHEMBL16237206 | 0.79 | VCAM1 (0.52) | VCAM1XDHALDH1A1CYP3A4LMNA | |
| SCHEMBL30589097 | 0.79 | XDH (0.66) | VCAM1XDHALDH1A1CYP3A4LMNA | |
| SCHEMBL14744347 | 0.79 | VCAM1 (0.52) | VCAM1XDHALDH1A1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | disclosed |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-12-05 | — | — | US | disclosed |
| WO-2024172631-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | 주식회사 카나프테라퓨틱스 | 2024-08-22 | — | — | WO | disclosed |
| EP-4389738-A1 | SOS1 INHIBITOR AND USE THEREOF | Kanaph Therapeutics Inc. (KR) | 2024-06-26 | — | — | EP | disclosed |
| CN-118119600-A | SOS1 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2534156-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| WO-2011100502-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI Pharmaceuticals, LLC (US) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | VCAM1 3562/4885XDH 1992/4885ALDH1A1 490/4885 |
| US-20240400518-A1 | SOS1 INHIBITOR AND USE THEREOF | SOS1, RAC1, SOS2 | VCAM1 1296/4885XDH 948/4885ALDH1A1 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.